Annexon Cash Flow Statement
NASDAQ: ANNXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
4.02+0.02 (+0.50%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Annexon free cash flow
In fiscal 2025, Annexon generated -$186.4 million of operating cash flow and spent $137,000 on capital expenditures. That left free cash flow of -$186.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Annexon cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Net Income | -206.69M | -138.20M | -134.24M | -141.95M | -130.32M | -63.41M | -37.18M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| Depreciation & Amortization | 2.17M | 2.15M | 2.15M | 2.11M | 2.14M | 667.00K | 493.00K |
| Stock-Based Compensation | 16.42M | 19.43M | 18.18M | 18.52M | 16.26M | 4.89M | 2.04M |
| Change in Working Capital | 12.31M | 11.93M | -4.30M | 5.43M | 2.02M | 4.99M | 967.00K |
| Operating Cash Flow | -186.36M | -118.01M | -121.14M | -116.31M | -106.11M | -53.09M | -28.36M |
| Capital Expenditures | -137.00K | -15.00K | -193.00K | -6.53M | -1.65M | -464.00K | -267.00K |
| Investing Cash Flow | 190.05M | -218.80M | 70.70M | 58.44M | -88.24M | -83.16M | -267.00K |
| Financing Cash Flow | 108.86M | 161.21M | 135.52M | 122.91M | 1.79M | 360.88M | 28.39M |
| Net Change in Cash | 112.55M | -175.60M | 85.08M | 65.04M | -192.55M | 224.63M | — |
| Free Cash Flow | -186.49M | -118.02M | -121.33M | -122.83M | -107.76M | -53.55M | -28.63M |
This table shows 7 annual periods of Annexon's cash flow statement, from FY 2025 back to FY 2019, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ANNX's reporting calendar. What is a cash flow statement?